Biotechnology Telemedicine Biotechnology Law In Russia.

1. Introduction

Biotechnology telemedicine law in Russia concerns the legal regulation of medical services delivered through digital communication technologies, including remote diagnosis, electronic prescriptions, genetic consultations, digital pathology, AI-assisted medical decision-making, remote patient monitoring and biotechnology-based healthcare.

Telemedicine is particularly important in biotechnology because modern healthcare increasingly depends on:

Genetic testing and genomic data analysis.

Remote monitoring of biological indicators.

AI-assisted diagnosis and treatment recommendations.

Digital pathology and molecular diagnostics.

Remote clinical-trial supervision.

Personalized medicine and precision healthcare.

Biotechnology-based treatment monitoring.

Russian law regulates these activities through medical legislation, personal-data protection, information technology rules, pharmaceutical regulation and professional liability principles.

The principal legal foundation is Federal Law No. 323-FZ of 21 November 2011, On the Fundamentals of Health Protection of Citizens in the Russian Federation, particularly Article 36.2, which governs the use of telemedicine technologies.

An important distinction is that telemedicine is not a separate licence to practise medicine. Where a service constitutes medical activity, the applicable medical licensing and professional requirements continue to apply.

2. Constitutional and Legislative Framework

The Russian Constitution provides the broader foundation for healthcare regulation.

Article 41 of the Constitution recognises the right to health protection and medical assistance. This principle supports the development of accessible healthcare services, including technology-enabled medical consultations.

The principal legislation includes:

LegislationLegal significance
Constitution of the Russian Federation, Article 41Right to health protection and medical assistance
Federal Law No. 323-FZ (2011)General healthcare framework and telemedicine
Federal Law No. 152-FZ (2006)Personal-data and health-data protection
Federal Law No. 149-FZ (2006)Information, information technologies and information protection
Federal Law No. 61-FZ (2010)Circulation of medicines
Federal Law No. 38-FZ (2006)Advertising regulation, including medical advertising
Government licensing regulationsLicensing of medical activities

These laws operate together. A telemedicine platform must consider not only the legality of remote consultations but also patient consent, confidentiality, cybersecurity, medical licensing and the legal status of digital medical products.

3. Article 36.2: Legal Regulation of Telemedicine

Article 36.2 is the central statutory provision governing telemedicine in Russia. It was introduced by Federal Law No. 242-FZ of 29 July 2017.

It establishes several important legal requirements.

A. Remote medical consultations

Doctors may communicate with patients or their legal representatives through telemedicine technologies for:

Prevention of diseases.

Collection and analysis of patient complaints.

Review of medical history.

Evaluation of treatment effectiveness.

Monitoring of the patient's health.

Determining whether an in-person examination is necessary.

B. Restrictions on remote diagnosis and treatment

Russian law generally distinguishes between an initial medical assessment and the subsequent adjustment of an established treatment plan.

Under Article 36.2(3), a treating doctor may adjust previously prescribed treatment remotely, provided that the doctor has established the diagnosis and prescribed the treatment during an in-person appointment.

This restriction is particularly relevant to biotechnology-based treatment, including:

Gene-therapy follow-up.

Cell-therapy monitoring.

Genetic disease management.

Remote monitoring of patients receiving biological medicines.

A telemedicine consultation should not be treated as an unrestricted substitute for all physical medical examinations.

C. Remote patient monitoring

Article 36.2(4) permits remote monitoring following an in-person consultation with the treating doctor.

Monitoring may rely on information collected through:

Registered medical monitoring devices.

Digital health records.

The Unified State Health Information System.

Regional healthcare information systems.

Other legally recognised medical information systems.

D. Medical confidentiality

Article 36.2(5) requires compliance with personal-data legislation and medical confidentiality.

E. Identification and authentication

Article 36.2(6) provides for the use of the Unified System of Identification and Authentication (ESIA) to identify and authenticate participants in remote medical interactions, subject to applicable statutory exceptions.

F. Electronic medical documentation

Article 36.2(7) requires medical information, including information entered into medical records, to be documented using the medical worker's enhanced qualified electronic signature.

These provisions establish the legal foundation for trustworthy digital healthcare.

Consultant Plus+1

 

4. New Telemedicine Rules: Ministry of Health Order No. 193n of 2025

A significant development occurred in 2025.

The Russian Ministry of Health adopted Order No. 193n of 11 April 2025, establishing a new procedure for organising and providing medical care using telemedicine technologies.

It entered into force on 1 September 2025 and is scheduled to remain effective until 1 September 2031.

It replaced the earlier Order No. 965n of 30 November 2017.

The new framework regulates:

Remote communication between healthcare professionals.

Consultations between doctors and patients.

Remote medical consultations and medical councils.

Real-time consultations.

Deferred or asynchronous consultations.

Digital medical documentation.

Remote monitoring of patients.

Use of clinical decision-support systems, including qualifying AI-based medical software.

An important development is the express recognition of AI-based clinical decision-support systems that qualify as medical devices and are registered under the applicable Russian medical-device rules.

For biotechnology companies, this is significant because AI systems can assist with genomic interpretation, molecular diagnostic assessments and biological treatment monitoring. However, software cannot avoid medical-device regulation merely by being described as an AI platform.

dgp140.mos.ru+2

5. Biotechnology and Telemedicine: Areas of Legal Application

A. Genetic testing and genomic counselling

Telemedicine enables patients to receive remote explanations of genetic testing results and hereditary disease risks.

For example, a biotechnology laboratory may analyse a patient's genetic sample and provide molecular diagnostic results to a licensed medical organisation.

The legal questions include:

Whether genetic information has been obtained and processed lawfully.

Whether the patient has provided appropriate informed consent.

Whether the genetic interpretation is medically reliable.

Whether the professional providing the consultation is qualified.

Whether the medical organisation complies with confidentiality requirements.

Genetic information may constitute sensitive personal data because it relates to health and biological characteristics.

B. AI-assisted biotechnology diagnosis

AI-based medical software may assist doctors in analysing:

Genomic sequencing results.

Molecular biomarkers.

Digital pathology images.

Tumour characteristics.

Biological test results.

However, the doctor and medical organisation cannot automatically transfer their legal responsibilities to the software developer.

The software's regulatory status, intended medical purpose, accuracy, validation and registration must be examined.

C. Remote monitoring of biological therapies

Patients receiving biological medicines, including certain immunotherapies and cell-based treatments, may require continuing clinical monitoring.

Telemedicine can facilitate:

Monitoring of vital signs.

Review of laboratory results.

Detection of adverse reactions.

Treatment-effectiveness assessment.

Follow-up consultations.

The treating doctor must determine when remote monitoring is insufficient and an in-person examination or emergency intervention is necessary.

D. Clinical trials and biotechnology research

Telemedicine may support communication between clinical investigators, research institutions and trial participants.

Nevertheless, remote communication does not remove the requirements of applicable clinical-trial regulations, ethical review, informed consent, safety reporting and research documentation.

E. Personalised medicine

Personalised medicine combines genomic information, molecular biomarkers and individual clinical characteristics.

Telemedicine provides a digital channel for discussing test results and coordinating treatment.

The legal challenge is to ensure that personalised treatment recommendations remain supported by appropriate medical evidence and are made by appropriately qualified professionals.

6. Personal Data Protection and Genetic Information

The most important legislation in this area is Federal Law No. 152-FZ of 27 July 2006, On Personal Data.

Article 10 regulates special categories of personal data, including information concerning health.

Biotechnology telemedicine services may process:

Genetic profiles.

DNA sequencing results.

Medical histories.

Laboratory reports.

Biomarker information.

Information about hereditary diseases.

Digital health-monitoring records.

Important compliance obligations include:

1. Lawful processing: The organisation must identify an appropriate legal basis for collecting and processing personal information.

2. Informed consent: Where consent is the applicable legal basis, the patient must receive appropriate information about the processing.

3. Data security: Medical organisations must implement appropriate organisational and technical safeguards.

4. Confidentiality: Medical information must not be improperly disclosed to third parties.

5. Data localisation: Russian personal-data localisation requirements must be considered when collecting personal data of Russian citizens through internet-based services.

6. International transfers: Cross-border transmission of genetic and medical information must comply with the applicable requirements of Russian personal-data law, including Article 12 of Federal Law No. 152-FZ.

A foreign biotechnology company providing genomic consultations to Russian patients must therefore assess its data-processing arrangements, international transfer procedures and relationships with Russian medical organisations.

The requirements of Article 36.2 of Law No. 323-FZ and Law No. 152-FZ must be considered together.

7. Medical Licensing and Liability of Telemedicine Providers

Telemedicine providers must comply with Russian medical licensing requirements.

A company operating a digital healthcare platform should distinguish between:

Providing communication or software infrastructure.

Providing medical consultations.

Conducting laboratory diagnostics.

Developing medical-device software.

Supplying or administering biotechnology-based medicines.

These activities may attract different regulatory requirements.

Relevant legislation

Federal Law No. 99-FZ of 4 May 2011 – Licensing of Certain Types of Activities.

Federal Law No. 323-FZ – Medical activities and patient rights.

Federal Law No. 61-FZ – Regulation of medicines.

Federal Law No. 152-FZ – Personal-data protection.

Potential grounds of liability

ConductPossible legal consequences
Incorrect remote diagnosisCivil liability for medical negligence
Failure to refer a patient for physical examinationMedical malpractice liability
Unlawful disclosure of genetic dataPersonal-data and confidentiality liability
Unregistered medical softwareRegulatory enforcement
Incorrect AI-generated medical recommendationsPotential liability of relevant medical and technology providers
Failure to maintain medical recordsAdministrative and professional consequences
Improper prescription or treatment adjustmentMedical and pharmaceutical regulatory liability

Under Article 98 of Federal Law No. 323-FZ, medical organisations and medical professionals may be liable for violations of healthcare rights and harm caused during medical assistance.

Articles 1064 and 1099–1101 of the Russian Civil Code are also relevant to compensation for injury and moral harm.

Importantly, responsibility for an AI-assisted diagnostic error depends on the facts, the applicable regulatory requirements, the conduct of the doctor and organisation, and the role of the software developer. It is not automatically imposed on one particular participant.

8. Important Russian Case Laws and Judicial Decisions

Russian courts have not yet developed a large, specialised body of biotechnology-telemedicine jurisprudence. Nevertheless, actual telemedicine judgments and wider medical-liability decisions provide important legal principles.

Case 1. Bondarchuk v. Regional Healthcare Authorities

Direct telemedicine case

Court: Ninth Court of Cassation of General Jurisdiction

Date: 6 February 2025

Case No.: 8Г-12682/2024 (88-819/2025)

Facts of the case

The dispute concerned a child's medical treatment and an online consultation involving a regional children's hospital and the child's treating physician.

The child's mother requested an online consultation in which she could participate. However, the consultation conducted on 5 October 2023 took place in a doctor-to-doctor format.

The consultation concerned confirmation of the child's basic treatment for the following year.

The mother challenged the consultation protocol and sought compensation for moral harm, arguing that the consultation had not been conducted in the requested format and that its documentation contained inaccurate information.

Legal issues

Whether a doctor-to-doctor telemedicine consultation was legally permissible.

Whether the patient's parent had to participate.

Whether the medical consultation protocol was unlawful.

Whether the healthcare authorities were liable for moral harm.

Judgment

The Ninth Cassation Court upheld the lower courts' conclusions rejecting the mother's claims.

The courts found that:

The consultation had been initiated by the treating doctor.

It was conducted between medical professionals for a legitimate clinical purpose.

The information in the protocol was consistent with the available medical documentation.

The consultation and recommendations had not been shown to violate the child's interests.

The applicable rules did not require the parent's participation in that particular doctor-to-doctor consultation.

Legal significance

This judgment demonstrates that telemedicine does not always require direct patient participation.

It also establishes the importance of distinguishing between:

Doctor-to-doctor consultations.

Doctor-to-patient consultations.

Consultations involving a patient's legal representative.

For biotechnology healthcare providers, the principle is relevant to remote genomic consultations, specialist review of molecular diagnostic reports and multidisciplinary clinical discussions.

ГАРАНТ

Case 2. Russian Supreme Court – Medical Negligence and Compensation for Moral Harm

Important analogous precedent

Court: Supreme Court of the Russian Federation

Date: 16 May 2022

Case No.: 18-КГПР22-28-К4

Facts

The case concerned a claim for compensation for moral harm arising from medical assistance.

The dispute involved the legal assessment of harm and whether the lower courts had properly examined the circumstances surrounding the medical treatment.

Legal issues

The Supreme Court considered the application of civil liability principles to medical assistance and the proper assessment of claims for moral harm.

Judgment

The Supreme Court overturned the earlier judicial decisions and sent the matter for reconsideration.

The decision emphasised the need for a proper judicial assessment of medical circumstances and the legal basis for compensation.

Legal significance

The decision is relevant to telemedicine because remote healthcare remains subject to ordinary medical-liability principles.

For example, if a doctor incorrectly interprets a genomic test, fails to identify a serious adverse biological reaction or provides inappropriate remote treatment advice, the resulting harm may give rise to a compensation claim.

The fact that the consultation took place electronically does not itself eliminate medical responsibility.

ГАРАНТ

Case 3. Russian Supreme Court – Standards for Assessing Defective Medical Assistance

Relevant authority: Resolution of the Plenum of the Supreme Court of the Russian Federation No. 33 of 15 November 2022, concerning the application of legal rules on compensation for moral harm.

This is a judicial interpretative authority rather than a separate telemedicine judgment.

Legal principles

Courts assessing claims involving defective medical assistance must examine matters including:

Whether appropriate diagnostic measures were taken.

Whether medical assistance complied with applicable procedures and standards.

Whether clinical recommendations were followed.

Whether the identified defects affected diagnosis or treatment.

Whether those defects caused or contributed to deterioration in the patient's health.

Whether the patient's rights were violated.

Application to biotechnology telemedicine

These principles are particularly important when:

An AI system misinterprets genomic data.

A remote doctor fails to recognise a serious clinical warning.

A laboratory result is incorrectly communicated.

A patient receiving cell therapy is inadequately monitored.

A telemedicine provider fails to arrange necessary physical examination.

The court must examine the actual medical evidence and causal connection rather than assuming that every adverse outcome establishes negligence.

Sudact

9. Judicial Principles Emerging from Russian Telemedicine Law

The statutory framework and available judicial decisions support the following principles:

PrincipleLegal interpretation
Patient protectionRemote healthcare must protect patient rights
Professional responsibilityDoctors retain their professional duties
Proper documentationConsultation records must be legally documented
Medical confidentialityGenetic and health data require protection
Clinical necessityPhysical examination must be arranged where necessary
Evidence-based treatmentMedical decisions must comply with applicable standards
CausationCompensation requires examination of the relevant harm and legal responsibility

These principles are relevant to biotechnology-based digital healthcare even where a dispute does not directly involve telemedicine legislation.

10. Artificial Intelligence and Telemedicine Regulation

AI is increasingly important in Russian biotechnology and digital medicine.

Examples include:

AI-based cancer detection.

Automated genetic mutation analysis.

Predictive diagnosis of hereditary diseases.

AI-supported drug-response prediction.

Remote analysis of pathological images.

Automated monitoring of biological treatment outcomes.

Order No. 193n of 2025 recognises the use of qualifying medical-device software incorporating AI in deferred telemedicine consultations.

However, the following legal questions remain important:

A. Algorithmic accountability

Who bears responsibility when an AI system produces an incorrect medical recommendation?

The answer depends on the respective responsibilities of the doctor, medical organisation, software developer and manufacturer.

B. Medical-device registration

AI software performing a regulated medical function may require registration as a medical device under Russian law.

C. Transparency

Medical professionals should be able to assess the relevance and reliability of AI-generated recommendations.

D. Patient protection

AI-assisted decision-making must not undermine informed consent, medical confidentiality or the patient's statutory rights.

11. Cross-Border Biotechnology Telemedicine

Cross-border telemedicine creates additional legal complications when Russian patients receive remote consultations from foreign biotechnology specialists.

For example, a Russian patient might send genomic sequencing information to a foreign laboratory and receive an AI-generated report from an overseas medical specialist.

The principal legal issues include:

Foreign medical licensing: Whether the foreign provider is legally authorised to provide the relevant medical service in the circumstances.

Genetic-data transfers: Whether international transmission complies with Article 12 of Federal Law No. 152-FZ.

Medical confidentiality: Whether foreign recipients maintain appropriate confidentiality.

Medical liability: Which country's law governs a dispute.

Electronic documentation: Whether foreign medical records can be recognised and used appropriately in Russian healthcare.

Pharmaceutical regulation: Whether medicines recommended through foreign consultations may legally be prescribed and supplied in Russia.

Cybersecurity: Whether the digital platform adequately protects sensitive biological information.

A foreign telemedicine platform should not assume that permission to operate in its home country automatically authorises it to provide regulated medical services in Russia.

12. Regulatory Challenges in Russia

Several challenges affect the development of biotechnology telemedicine.

ChallengeLegal concernPossible regulatory response
AI diagnostic errorsUnclear allocation of responsibilityClearer liability standards
Genetic-data misusePrivacy violationsStronger genetic-data safeguards
Remote treatment limitationsInadequate physical examinationClinical referral requirements
Cross-border consultationsConflicting legal systemsInternational cooperation
Digital-platform failuresInterrupted healthcareCybersecurity standards
Medical software defectsIncorrect diagnostic resultsMedical-device supervision
Biotechnology monitoringDelayed detection of complicationsImproved monitoring protocols

13. Practical Compliance Requirements for Biotechnology Companies

A biotechnology company establishing a telemedicine service in Russia should consider the following compliance framework.

Russian biotechnology telemedicine compliance checklist

Determine whether the proposed service constitutes regulated medical activity.

Obtain the necessary medical licences where applicable.

Comply with Article 36.2 of Federal Law No. 323-FZ.

Follow Ministry of Health Order No. 193n of 2025.

Establish patient identification and authentication procedures.

Obtain appropriate informed consent.

Comply with Federal Law No. 152-FZ concerning health and genetic information.

Assess medical-device registration requirements for diagnostic software.

Maintain electronic medical documentation and appropriate electronic signatures.

Establish procedures for clinical escalation and emergency referrals.

Maintain appropriate cybersecurity and incident-response procedures.

Review international data transfers and foreign-provider arrangements.

14. Critical Legal Analysis

Russian biotechnology telemedicine regulation reflects an attempt to balance technological innovation with patient safety.

The legislation provides a legal foundation for remote consultations, monitoring and digital medical records. The 2025 regulatory framework also accommodates certain AI-based medical decision-support systems.

Nevertheless, several difficult questions remain.

First, the distinction between consultation and treatment: Remote consultations are permitted for specified purposes, but the statutory requirements concerning initial diagnosis and treatment adjustment can restrict fully remote treatment models.

Second, genetic-data protection: Genetic information has continuing implications for patients and potentially their biological relatives. Conventional medical-data safeguards may not resolve every issue involving familial genetic information.

Third, AI responsibility: The allocation of liability among healthcare professionals, medical organisations and software developers requires careful examination.

Fourth, technological reliability: Biotechnology telemedicine depends on accurate laboratory testing, reliable data transmission and scientifically validated diagnostic systems.

Fifth, cross-border regulation: International genomic consultations create difficult questions involving data localisation, international transfers, professional qualifications and jurisdiction.

Consequently, the effectiveness of Russian biotechnology telemedicine law depends not only on digital innovation but also on the quality of medical supervision, legal accountability and protection of biological information.

15. Conclusion

Biotechnology telemedicine law in Russia is governed primarily by Federal Law No. 323-FZ, particularly Article 36.2, together with Federal Laws Nos. 152-FZ, 149-FZ and 61-FZ and the applicable medical licensing and medical-device regulations.

Ministry of Health Order No. 193n of 2025 represents an important regulatory development because it establishes updated procedures for remote medical consultations, professional interaction, deferred consultations and remote patient monitoring.

The Ninth Court of Cassation's decision in Case No. 8Г-12682/2024 is particularly relevant because it directly addresses the legality of a doctor-to-doctor telemedicine consultation.

The Supreme Court's medical-liability jurisprudence further demonstrates that digital healthcare providers remain subject to ordinary principles of patient protection, professional responsibility and compensation for harm.

Ultimately, Russia's biotechnology telemedicine framework must ensure that digital healthcare advances do not compromise medical quality, genetic privacy, patient autonomy and legal accountability.

16. Important Legal References

Legal authoritySubject
Russian Constitution, Article 41Right to healthcare
Federal Law No. 323-FZ (2011), Article 36.2Telemedicine
Federal Law No. 152-FZ (2006)Personal-data protection
Federal Law No. 149-FZ (2006)Information technology
Federal Law No. 61-FZ (2010)Medicines
Federal Law No. 99-FZ (2011)Licensing
Federal Law No. 258-FZ (2020)Experimental legal regimes for digital innovation
Ministry of Health Order No. 193n (2025)Telemedicine procedures
Civil Code, Articles 1064, 1099–1101Compensation and civil liability
Supreme Court Plenum Resolution No. 33 (2022)Moral-harm compensation

Primary and further legal research sources

Article 36.2 – Federal Law No. 323-FZ.

Ministry of Health Order No. 193n of 2025.

Ninth Court of Cassation – Case No. 8Г-12682/2024.

Russian Supreme Court – Case No. 18-КГПР22-28-К4.

Academic research: Legal Regulation of Telemedicine in Russia.

Research note: The cases discussed above should be distinguished carefully: the 2025 Ninth Cassation decision directly concerns telemedicine, while the Supreme Court decision and Plenum Resolution provide broader medical-liability principles. They should not be represented as judgments specifically deciding biotechnology or genomic telemedicine disputes.

LawGratis provides pro bono legal aid and resources to empower communities. Join us in making justice reachable for everyone! Follow our community on Instagram, YouTube, Facebook, and LinkedIn.

LEAVE A COMMENT